日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Comparison of Immune Responses and Safety Profiles Following a Fourth Heterologous Dose (Second Booster) with mRNA-1273 in Individuals Previously Vaccinated with Two Doses of CoronaVac and a Booster Dose of Either AZD1222 or BNT162b2

对先前已接种两剂 CoronaVac 疫苗和一剂 AZD1222 或 BNT162b2 加强剂的个体,在接种第四剂异源疫苗(第二次加强针)后,使用 mRNA-1273 的免疫反应和安全性概况进行比较

Tangsathapornpong, Auchara; Nanthapisal, Sira; Fukpho, Waraphon; Bunjoungmanee, Pornumpa; Neamkul, Yamonbhorn; Pontan, Kanassanan; Boonyarangkul, Arthit; Wanpen, Supattra; Thongphubeth, Kanokporn; Tharabenjasin, Phuntila; Jaru-Ampornpan, Peera

Specific IgE to tropomyosin increases the diagnostic accuracy of shrimp allergy

针对原肌球蛋白的特异性IgE可提高虾过敏的诊断准确性

Kulalert, Prapasri; Kreetapirom, Piyawut; Piboonpocanun, Surapon; Jirapongsananuruk, Orathai; Authong, Nattakan; Khodtecha, Nantika; Poachanukoon, Orapan; Nanthapisal, Sira

Immune responses after two inactivated COVID-19 vaccine doses, a heterologous third dose and subsequent boosting with bivalent mRNA in adults

成人接种两剂灭活新冠疫苗、一剂异源第三剂疫苗以及随后接种二价mRNA加强针后的免疫反应

Muangnoicharoen, Sant; Lawpoolsri, Saranath; Cowan, Juthaporn; Luvira, Viravarn; Jongkaewwattana, Anan; Nanthapisal, Sira; Phumratanaprapin, Weerapong; Kamolratanakul, Supitcha; Thanthamnu, Narumon; Duangdee, Chatnapa; Pitisuttithum, Punnee

Real-world immune response to SARS-CoV-2 vaccination in Thai patients with systemic lupus erythematosus: a cross-sectional observational study

泰国系统性红斑狼疮患者接种SARS-CoV-2疫苗后的真实免疫反应:一项横断面观察研究

Pongkulkiat, Patnarin; Foocharoen, Chingching; Nanthapisal, Sira; Phanthanawiboon, Supranee; Meesing, Atibordee; Suwannaroj, Siraphop; Mootsikapun, Piroon; Mahakkanukrauh, Ajanee

Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines

新冠疫苗过敏反应的发生率及相关因素(自我报告的皮肤症状)

Thanborisutkul, Karnsinee; Kulalert, Prapasri; Methaset, Kanthida; Nanthapisal, Sira; Chunthatikul, Tibet; Phangpanya, Nathamon; Charoenying, Phenpraphatson; Atsawutmangkru, Worakamon; Srijaroen, Suphatsara; Punyashthira, Patcharaporn; Poachanukoon, Orapan

Clean Air for Asthma and Allergy Programme (CAAP), a randomized controlled trial to evaluate the effectiveness of multicomponent interventions to reduce indoor triggers in childhood asthma

“清洁空气哮喘和过敏计划”(CAAP)是一项随机对照试验,旨在评估多组分干预措施在减少儿童哮喘室内诱发因素方面的有效性。

Det-Amnatkul, Wiphada; Kulalert, Prapasri; Nanthapisal, Sira; Poachanukoon, Orapan

Allergic rhinitis and urticaria burden and antihistamine treatment options in Thailand: A modified Delphi study

泰国过敏性鼻炎和荨麻疹的负担及抗组胺治疗方案:一项改良的德尔菲研究

Chantaphakul, Hiroshi; Chiewchalermsri, Chirawat; Mairiang, Dara; Lao-Araya, Mongkol; Piboonpocanun, Orathai; Nanthapisal, Sira; Mitthamsiri, Wat; Kamchaisatian, Wasu; Manuyakorn, Wiparat; Sangsupawanich, Pasuree

Promoting patient-centred care in the management of allergic rhinitis in Asia-Pacific countries

在亚太地区国家推广以患者为中心的过敏性鼻炎治疗

Chantaphakul, Hiroshi; Wang, De Yun; Hang, Tran Thi Thuy; Kadir, Khizuan Abdul; Lam, Hoang Thi; Navarro-Locsin, Cecilia Gretchen; Nanthapisal, Sira; Poblete, Danilo; Tantilipikorn, Pongsakorn; Tong, Wong Hui; Nagrale, Dinesh; Lucas, Michaela

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?

在以 Omicron 变异株为主的疫情大流行期间,COVID-19 疫苗的实际有效性:我们需要多少剂加强针?

Sritipsukho, Paskorn; Khawcharoenporn, Thana; Siribumrungwong, Boonying; Damronglerd, Pansachee; Suwantarat, Nuntra; Satdhabudha, Araya; Chaiyakulsil, Chanapai; Sinlapamongkolkul, Phakatip; Tangsathapornpong, Auchara; Bunjoungmanee, Pornumpa; Nanthapisal, Sira; Tanprasertkul, Chamnan; Sritipsukho, Naiyana; Mingmalairak, Chatchai; Apisarnthanarak, Anucha; Tantiyavarong, Pichaya

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol

中重度儿童哮喘的管理:丙酸氟替卡松/沙美特罗疗效和安全性的范围综述

Pitrez, Paulo Marcio; Nanthapisal, Sira; Castro, Ana Paula Beltran Moschione; Teli, Chirag; P G, Abhijith